No abstract

Twenty-two Standardbred horses in race training were used in a crossover experiment to determine the effect of oral sodium bicarbonate (NaHCO3) administration on performance and metabolic responses to a 1.6-km (1-mile) race. Horses were paired and one horse in each pair was treated with either NaHCO3 (300 mg/kg BW) or a placebo, 2.5 h before they raced against each other. Each horse was scheduled to compete in two races, approximately 1 wk apart, one on each treatment. Horses always raced in the same pairs. Fourteen horses successfully completed both races. Jugular blood samples were obtained 1.5 h after treatment (rest), immediately before racing, 5 min post-race and 15 min post-race. In six horses, blood samples also were obtained 30 min post-race. Race times averaged 1.1 s faster after NaHCO3 treatment (P less than .1). Sodium bicarbonate treatment also elevated blood pH (P less than .05). In the horses sampled 15 and 30 min post-race, blood lactate disappearance was faster with the NaHCO3 treatment (P less than .05). The NaHCO3 may delay the fatigue precipitated by i.m. acidosis. Because other factors may limit performance (musculoskeletal soundness, cardiovascular and respiratory ability), NaHCO3 would not be expected to enhance the performance of all horses. However, the effect of NaHCO3 on lactate clearance may have implications for all intensively worked horses; because lactate and the associated hydrogen ions are believed to cause muscle damage and soreness, any mechanism to increase their removal rate could benefit the equine athlete.

No abstract

No abstract

No abstract

Six conditioned Quarter Horse mares were used in a crossover design to assess the effect of the dietary protein level on intramuscular and hepatic glycogen and lactate, oxygen uptake and blood lactate, pyruvate and free fatty acids. After a 2-wk adaptation period to either a 9.0% (control) or an 18.5% crude protein diet, each horse performed an exercise test. The horses were exercised for 15 min on an 11% grade treadmill at 4.5 m/sec. The exercise test was performed 3-4 h after a meal. Venous, arterial and mixed-venous blood samples were taken simultaneously at rest and during exercise. Muscle and liver samples were taken at rest and after exercise. The dietary protein level did not affect hepatic or intramuscular glycogen utilization (P greater than 0.05). Exercise resulted in increased (P less than 0.001) lactate in venous blood, muscle and liver; however, dietary treatment did not affect (P greater than 0.05) lactate level. Venous blood lactate:pyruvate ratio was higher (P less than 0.05) in the control horses. Dietary protein level did not affect (P greater than 0.05) oxygen uptake or plasma free fatty acids; however, exercise increased (P less than 0.01) both. These results indicate the dietary protein did not affect substrate utilization during the absorptive phase of digestion in exercising horses; however, the higher lactate:pyruvate ratio in the control horses suggests that the intraconversion of lactate and pyruvate may be influenced by diet composition.

No abstract

A highly sensitive flavin adenine dinucleotide-3'-phosphate (FADP)-based enzyme amplification cascade has been developed for determining alkaline phosphatase (ALP; EC 3.1.3.1). The cascade detects ALP via the dephosphorylation of the novel substrate FADP to produce the cofactor FAD, which binds stoichiometrically to inactive apo D-amino acid oxidase (D-AAO). The resulting active holo D-AAO oxidizes D-proline to produce hydrogen peroxide, which is quantified by the horseradish peroxidase-mediated conversion of 3,5-dichloro-2-hydroxybenzenesulfonic acid and 4-aminoantipyrine to a colored product. The FADP-based enzyme amplification cascade has been used in a novel releasable linker immunoassay (RELIA) to quantify thyrotropin (TSH). In the assay, TSH is first captured onto antibody-coated chromium dioxide particles. After formation of an antibody-TSH sandwich with a dethiobiotinylated second antibody, the complex is reacted with a streptavidin-ALP conjugate. Biotin is then used to release the conjugate into solution, and ALP is quantified in an automated version of the FADP-based amplification cascade on the aca discrete clinical analyzer (Du Pont). The sensitivity of the colorimetric RELIA assay for TSH (less than 0.1 milli-int. unit/L) is comparable with that of fluorometric assays. This technology provides a way to adapt to the aca high-sensitivity immunoassays for a wide range of analytes via colorimetric detection.